Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) EPS (Basic) (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed EPS (Basic) for 6 consecutive years, with -$7.68 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 46.67% to -$7.68 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$12.88 through Dec 2025, up 40.67% year-over-year, with the annual reading at -$16.06 for FY2025, 38.77% up from the prior year.
  • EPS (Basic) hit -$7.68 in Q4 2025 for Lyell Immunopharma, down from -$2.13 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.03 in Q4 2022 to a low of -$17.97 in Q4 2023.
  • Historically, EPS (Basic) has averaged -$2.95 across 5 years, with a median of -$0.28 in 2022.
  • Biggest five-year swings in EPS (Basic): soared 92.22% in 2021 and later plummeted 59800.0% in 2023.
  • Year by year, EPS (Basic) stood at -$0.18 in 2021, then surged by 83.33% to -$0.03 in 2022, then tumbled by 59800.0% to -$17.97 in 2023, then grew by 19.87% to -$14.4 in 2024, then skyrocketed by 46.67% to -$7.68 in 2025.
  • Business Quant data shows EPS (Basic) for LYEL at -$7.68 in Q4 2025, -$2.13 in Q3 2025, and -$2.89 in Q2 2025.